Description

Additional validation experiments for melatonin's effects on the SIRT1-DNMT1-CES1 epigenetic axis in castration-resistant prostate cancer.

Figure 27

Chart

Source Paper

Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.

Clinical and translational medicine (2021)

PMID: 34185414

DOI: 10.1002/ctm2.449

Cite This Figure

![Figure 27: Additional validation experiments for melatonin's effects on the SIRT1-DNMT1-CES1 epigenetic axis in castration-resistant prostate cancer.]()

> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)

<figure>
  <img src="" alt="Additional validation experiments for melatonin's effects on the SIRT1-DNMT1-CES1 epigenetic axis in castration-resistant prostate cancer." />
  <figcaption>Figure 27. Additional validation experiments for melatonin's effects on the SIRT1-DNMT1-CES1 epigenetic axis in castration-resistant prostate cancer.<br>  Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption>
</figure>

Related Evidence

Melatonin for Circadian Rhythm Disorder

Grade A · 176 studies